| ［1］ |
中华人民共和国国家卫生健康委员会医政司.肥胖症中国诊疗指南（2024年版） ［J］.中华消化外科杂志，2024，23（10）：1237-1260.
|
| ［2］ |
Bessesen DH，Van Gaal LF.Progress and challenges in anti-obesity pharmacotherapy ［J］.The lancet Diabetes & endocrinology，2018，6（3）：237-248.
|
| ［3］ |
曲伸，陆灏，宋勇峰.基于临床的肥胖症多学科诊疗共识（2021年版）［J/CD］.中华肥胖与代谢病电子杂志，2021，7（4）：211-226.
|
| ［4］ |
Coskun T，Sloop K W，Loghin C，et al.LY3298176，a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus：From discovery to clinical proof of concept ［J］.Molecular metabolism，2018，18：3-14.
|
| ［5］ |
Nauck MA，D'Alessio DA.Tirzepatide，a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction［J］.Cardiovasc Diabetol，2022，21（1）：169.
|
| ［6］ |
Campbell JE，Drucker DJ.Pharmacology，physiology，and mechanisms of incretin hormone action ［J］.Cell Metab，2013，17（6）：819-837.
|
| ［7］ |
Nauck MA，Meier JJ.The incretin effect in healthy individuals and those with type 2 diabetes：physiology，pathophysiology，and response to therapeutic interventions ［J］.The lancet Diabetes & endocrinology，2016，4（6）：525-536.
|
| ［8］ |
Regmi A，Aihara E，Christe ME，et al.Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor ［J］.Cell metabolism，2024，36（7）：1534-1549.e7.
|
| ［9］ |
Forzano I，Varzideh F，Avvisato R，et al.Tirzepatide：A systematic update ［J］.International journal of molecular sciences，2022，23（23）：14631.
|
| ［10］ |
Aronne LJ，Sattar N，Horn DB，et al.Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity：The SURMOUNT-4 randomized clinical trial ［J］.Jama，2024，331（1）：38-48.
|
| ［11］ |
Moreira CG，Russell R，Mishra AA，et al.bacterial adrenergic sensors regulate virulence of enteric pathogens in the gut ［J］.mBio，2016，7（3）：e00826.
|
| ［12］ |
Valentí V，Cienfuegos JA，Becerril Mañas S，et al.Mechanism of bariatric and metabolic surgery：beyond surgeons，gastroenterologists and endocrinologists ［J］.Revista espanola de enfermedades digestivas，2020，112（3）：229-233.
|
| ［13］ |
Coluzzi I，Raparelli L，Guarnacci L，et al.Food intake and changes in eating behavior after laparoscopic sleeve gastrectomy ［J］.Obesity surgery，2016，26（9）：2059-2067.
|
| ［14］ |
Dischinger U，Kötzner L，Kovatcheva-Datchary P，et al.Hypothalamic integrity is necessary for sustained weight loss after bariatric surgery：A prospective，cross-sectional study ［J］.Metabolism：clinical and experimental，2023，138：155341.
|
| ［15］ |
Schauer PR，Bhatt DL，Kashyap SR.Bariatric surgery or intensive medical therapy for diabetes after 5 years ［J］.The New England journal of medicine，2017，376（20）：1997.
|
| ［16］ |
Salminen P，Grönroos S，Helmiö M，et al.Effect of laparoscopic sleeve gastrectomy vs roux-en-y gastric bypass on weight loss，comorbidities，and reflux at 10 years in adult patients with obesity：The SLEEVEPASS randomized clinical trial ［J］.JAMA Surg，2022，157（8）：656-666.
|
| ［17］ |
Albaugh VL，He Y，Münzberg H，et al.Regulation of body weight：Lessons learned from bariatric surgery ［J］.Molecular metabolism，2023，68：101517.
|
| ［18］ |
Dang JT，Mocanu V，Park H，et al.Roux-en-Y gastric bypass and sleeve gastrectomy induce substantial and persistent changes in microbial communities and metabolic pathways ［J］.Gut Microbes，2022，14（1）：2050636.
|
| ［19］ |
Le Chatelier E，Nielsen T，Qin J，et al.Richness of human gut microbiome correlates with metabolic markers ［J］.Nature，2013，500（7464）：541-546.
|
| ［20］ |
Liou AP，Paziuk M，Luevano JM，Jr.，et al.Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity ［J］.Science translational medicine，2013，5（178）：178ra41.
|
| ［21］ |
Rosenstock J，Wysham C，Frías JP，et al.Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes （SURPASS-1）：a double-blind，randomised，phase 3 trial ［J］.Lancet （London，England），2021，398（10295）：143-155.
|
| ［22］ |
Frías JP，Davies MJ，Rosenstock J，et al.Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes ［J］.The New England journal of medicine，2021，385（6）：503-515.
|
| ［23］ |
Ludvik B，Giorgino F，Jódar E，et al.Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes （SURPASS-3）：a randomised，open-label，parallel-group，phase 3 trial ［J］.Lancet（London，England），2021，398（10300）：583-598.
|
| ［24］ |
Del Prato S，Kahn SE，Pavo I，et al.Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk （SURPASS-4）：a randomised，open-label，parallel-group，multicentre，phase 3 trial ［J］.Lancet （London，England），2021，398（10313）：1811-1824.
|
| ［25］ |
Dahl D，Onishi Y，Norwood P，et al.Effect of subcutaneous Tirzepatide vs Placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes：The SURPASS-5 randomized clinical trial ［J］.Jama，2022，327（6）：534-545.
|
| ［26］ |
Jiang Y，Zhu H，Gong F.Why does GLP-1 agonist combined with GIP and/or GCG agonist have greater weight loss effect than GLP-1 agonist alone in obese adults without type 2 diabetes？ ［J］.Diabetes，obesity & metabolism，2025，27（3）：1079-1095.
|
| ［27］ |
Heise T，DeVries J H，Urva S，et al.Tirzepatide reduces appetite，energy intake，and fat mass in people with type 2 diabetes ［J］.Diabetes care，2023，46（5）：998-1004.
|
| ［28］ |
Jastreboff AM，Aronne LJ，Ahmad NN，et al.Tirzepatide once weekly for the treatment of obesity ［J］.The New England journal of medicine，2022，387（3）：205-216.
|
| ［29］ |
Müllertz ALO，Sandsdal RM，Jensen SBK，et al.Potent incretinbased therapy for obesity：A systematic review and meta-analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference，and safety ［J］.Obesity reviews，2024，25（5）：e13717.
|
| ［30］ |
孙雪，宋伟东，任淞泽，等.替西帕肽用于2型糖尿病治疗的研究进展 ［J］.中国医药科学 ［J］.2024，14（08）：33-6+77.
|
| ［31］ |
Sohal A，Casanova L，Kowdley KV.A Rare Case of Tirzepatide-Induced Hepatotoxicity ［J］.ACG Case Rep J，2024，11（10）：e01484.
|
| ［32］ |
Hartman ML，Sanyal AJ，Loomba R，et al.Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes ［J］.Diabetes care，2020，43（6）：1352-1355.
|
| ［33］ |
Lin F，Yu B，Ling B，et al.Weight loss efficiency and safety of tirzepatide：A systematic review ［J］.PloS one，2023，18（5）：e0285197.
|
| ［34］ |
Frias JP，Nauck MA，Van J，et al.Efficacy and tolerability of tirzepatide，a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes：A 12-week，randomized，double-blind，placebo-controlled study to evaluate different dose-escalation regimens ［J］.Diabetes，obesity & metabolism，2020，22（6）：938-946.
|
| ［35］ |
Jakobsen GS，Småstuen MC，Sandbu R，et al.Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities ［J］.Jama，2018，319（3）：291-301.
|
| ［36］ |
Ghiassi S，Morton JM.Safety and efficacy of bariatric and metabolic surgery ［J］.Current obesity reports，2020，9（2）：159-164.
|
| ［37］ |
O'Brien PE，Hindle A，Brennan L，et al.Long-term outcomes after bariatric surgery：a systematic review and meta-analysis of weight loss at 10 or more years for all bariatric procedures and a singlecentre review of 20-year outcomes after adjustable gastric banding ［J］.Obesity surgery，2019，29（1）：3-14.
|
| ［38］ |
Rubino F，Nathan DM，Eckel RH，et al.Metabolic surgery in the treatment algorithm for type 2 diabetes：a joint statement by international diabetes organizations ［J］.Obesity surgery，2017，27（1）：2-21.
|
| ［39］ |
Schauer PR，Bhatt DL，Kirwan JP，et al.Bariatric surgery versus intensive medical therapy for diabetes - 5-year outcomes ［J］.The New England journal of medicine，2017，376（7）：641-651.
|
| ［40］ |
Sjöström L，Lindroos AK，Peltonen M，et al.Lifestyle，diabetes，and cardiovascular risk factors 10 years after bariatric surgery ［J］.The New England journal of medicine，2004，351（26）：2683-2693.
|
| ［41］ |
Lee WJ，Chong K，Ser KH，et al.Gastric bypass vs sleeve gastrectomy for type 2 diabetes mellitus：a randomized controlled trial ［J］.Arch Surg，2011，146（2）：143-148.
|
| ［42］ |
McGlone ER，Carey I，Veličković V，et al.Bariatric surgery for patients with type 2 diabetes mellitus requiring insulin：Clinical outcome and cost-effectiveness analyses ［J］.PLoS medicine，2020，17（12）：e1003228.
|
| ［43］ |
Sandoval DA，Patti ME.Glucose metabolism after bariatric surgery：implications for T2DM remission and hypoglycaemia ［J］.Nature reviews Endocrinology，2023，19（3）：164-176.
|
| ［44］ |
van Veldhuisen SL，Gorter TM，van Woerden G，et al.Bariatric surgery and cardiovascular disease：a systematic review and metaanalysis ［J］.European heart journal，2022，43（20）：1955-1969.
|
| ［45］ |
Cohen RV，Pereira TV，Aboud CM，et al.Effect of gastric bypass vs best medical treatment on early-stage chronic kidney disease in patients with type 2 diabetes and obesity：A randomized clinical trial［J］.JAMA Surg，2020，155（8）：e200420.
|
| ［46］ |
Lee Y，Doumouras AG，Yu J，et al.Laparoscopic sleeve gastrectomy versus laparoscopic roux-en-y gastric bypass：A systematic review and meta-analysis of weight loss，comorbidities，and biochemical outcomes from randomized controlled trials ［J］.Annals of surgery，2021，273（1）：66-74.
|
| ［47］ |
王兵，王存川.减重代谢手术治疗肥胖合并阻塞性睡眠呼吸暂停——减重代谢外科视角 ［J］.中华肥胖与代谢病电子杂志，2018，4（02）：65-68.
|
| ［48］ |
Daigle CR，Brethauer SA，Tu C，et al.Which postoperative complications matter most after bariatric surgery？ Prioritizing quality improvement efforts to improve national outcomes ［J］.Surgery for obesity and related diseases，2018，14（5）：652-657.
|
| ［49］ |
Pareek M，Schauer PR，Kaplan LM，et al.Metabolic surgery：weight loss，diabetes，and beyond ［J］.J Am Coll Cardiol，2018，71（6）：670-687.
|
| ［50］ |
Qin W，Yang J，Ni Y，et al.Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo：An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial ［J］.Endocrine，2024，86（1）：70-84.
|
| ［51］ |
Sun Y，Liu B，Smith JK，et al.Association of preoperative body weight and weight loss with risk of death after bariatric surgery ［J］.JAMA network open，2020，3（5）：e204803.
|
| ［52］ |
Ard JD，Beavers DP，Hale E，et al.Use of phentermine-topiramate extended release in combination with sleeve gastrectomy in patients with BMI 50 kg/m（2） or more ［J］.Surgery for obesity and related disease，2019，15（7）：1039-1043.
|
| ［53］ |
Jamal M，Alhashemi M，Dsouza C，et al.Semaglutide and Tirzepatide for the management of weight recurrence after sleeve gastrectomy：a retrospective cohort study ［J］.Obesity surgery，2024，34（4）：1324-1332.
|
| ［54］ |
Buckley A，Suliman S，Allum M，et al.Real world use of tirzepatide in the treatment of type 2 diabetes in an Arab population ［J］.Diabetes，obesity & metabolism，2024，26（8）：3381-3391.
|
| ［55］ |
Stortz E，Lawler H.Tirzepatide improves early dumping syndrome and glucose nadir in postbariatric hypoglycemia after sleeve gastrectomy ［J］.JCEM case reports，2024，2（11）：luae194.
|
| ［56］ |
Freckmann G，Hagenlocher S，Baumstark A，et al.Continuous glucose profiles in healthy subjects under everyday life conditions and after different meals ［J］.Journal of diabetes science and technology，2007，1（5）：695-703.
|
| ［57］ |
Stahl JM，Malhotra S.Obesity Surgery Indications and Contraindications ［M］.StatPearls.Treasure Island （FL） ineligible companies.Disclosure：Sandeep Malhotra declares no relevant financial relationships with ineligible companies.； StatPearls Publishing Copyright © 2024，StatPearls Publishing LLC.2024.
|
| ［58］ |
Jalleh RJ，Rayner CK，Hausken T，et al.Gastrointestinal effects of GLP-1 receptor agonists：mechanisms，management，and future directions ［J］.The lancet Gastroenterology & hepatology，2024，9（10）：957-964.
|